Paper aims to explore questions surrounding cytoreductive nephrectomy
"Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed," says Jaleh Fallah, MD.
In this video, Jaleh Fallah, MD, discusses the motivation behind the Journal of the National Cancer Institute paper, “Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.” Fallah is a medical oncologist with the FDA.
Transcription:
Why did the FDA decide this project was worth conducting?
The Oncology Center of Excellence or OCE supports FDA oncology staff who participate in regulatory science research, including internal research projects and collaborations with external experts. Scientific research that can inform our regulatory work is part of our mission. Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed, particularly given the changes in the therapeutic landscape since those trials were conducted, and we didn't have access to the data needed to explore the study question.
This transcription was edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.
